Clinical trials: Japanese Encephalitis
Japanese Encephalitis
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged > or = 18 years
- Trial name
- NCT00605085
- Testing
- Japanese Encephalitis purified inactivated vaccine (IC51)
- Volunteers
- 2,675 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Safety Surveillance After Immunization With IXIARO
This is an active electronic surveillance using data from the Defense Medical Surveillance System (DMSS) to detect and characterize serious, rare adverse events occurring within 42 days after vaccination with the Japanese…
- Trial name
- NCT01335412
- Testing
- Japanese Encephalitis Virus vaccine, inactivated, adsorbed
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine
The purpose of this study is to assess the safety, tolerability, and immunogenicity of a new formulation of lyophilised ChimeriVax™-JE, given at three dose levels, compared with placebo.
- Trial name
- NCT00981630
- Testing
- Live attenuated Japanese encephalitis virus
- Where
- 2 sites in Australia
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Sanofi
Encephalitis, Japanese B
Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
The previously conducted JEV01 study looked at the immunogenicity and safety of the concurrent administration of Japanese Live Attenuated SA 14-14-2 and measles vaccines at the one month post vaccination time point.
- Trial name
- NCT00412516
- Testing
- Live attenuated SA 14-14-2 vaccine
- Where
- Philippines
- Volunteers
- 519 people, healthy volunteers welcome
- Sponsor
- PATH
Japanese Encephalitis
Flavivirus Cross-priming Potential of IMOJEV
There is a pressing need for a better experimental system to understand flavivirus antibody responses, beyond dengue, to make sure the investigators are using current vaccines to greatest effect and to inform the development of…
- Trial name
- FlaviPrime (NCT03920111)
- Testing
- IMOJEV
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Japanese Encephalitis Vaccine
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
The main objective of this study is to evaluate the persistence of Japanese encephalitis antibodies in participants at the age of 6, after they have followed different Japanese encephalitis vaccination schedules.
- Trial name
- NCT06825312
- Testing
- Japanese Encephalitis Vaccine (Vero Cell), Inactivated, Japanese Encephalitis Vaccine, Live
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Japanese Encephalitis
Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
The study investigates a rapid immunization regime of the Japanese Encephalitis vaccine IC51 (JE-PIV) in healthy subjects aged > or = 18 years
- Trial name
- NCT00595790
- Testing
- IC51
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
This is a randomized, open-label Phase 3 study including children aged >9 months to <17 years and 7 months who have been vaccinated with IXIARO in study IC51-323.
- Trial name
- NCT01296360
- Testing
- IXIARO
- Where
- 3 sites in Philippines
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Safety and Immunogenicity of JECEVAX in Young Children
A dose escalating study with 3 different dosing regimens of the studied vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the…
- Trial name
- NCT02816554
- Testing
- JEVAX, JECEVAX-1, JECEVAX-0.8
- Where
- 2 sites in Vietnam
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam
Tick-Borne Encephalitis
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
- Trial name
- NCT04648241
- Testing
- TBE vaccine 0.5 mL, TBE vaccine 0.25 mL
- Where
- 6 sites in Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Pfizer
Japanese Encephalitis
Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine
To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of co-administration of LJEV and…
- Trial name
- NCT00463476
- Testing
- Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)
- Where
- 3 sites in Sri Lanka
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- PATH
Japanese Encephalitis, Hepatitis A
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Safety: To describe the safety profiles following vaccination. Immunogenicity: To describe the immune response after a single dose of vaccine.
- Trial name
- NCT00621764
- Testing
- Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)
- Where
- 3 sites in Thailand
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
The objective is to assess immunogenicity of a commercial IC51 batch at 3 different time points post filling (12, 18, 24 months) in terms of Geometric Mean Titers (GMT) for anti-JEV neutralizing antibodies at Day 56 after the…
- Trial name
- NCT00776230
- Testing
- IC51
- Where
- 3 sites in Austria, Germany
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam
A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced…
- Trial name
- JECEVAX-3 (NCT03282370)
- Testing
- JEVAX, JECEVAX
- Where
- 4 sites in Vietnam
- Volunteers
- 655 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam
Iron Deficiency Anemia
Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity
Iron deficiency (ID) anaemia (IDA) is a global public health problem, with the highest prevalence in Africa and in South-East Asia.
- Trial name
- NCT06027801
- Testing
- Iron-fortified cookies, Japanese encephalitis (JE) vaccine, Typhoid Vi polysaccharide (Vi-PS) vaccine
- Where
- Thailand
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Japanese Encephalitis
Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate equivalence of three IC51 batches in terms of Geometric Mean Titers for anti-JEV neutralizing antibody.
- Trial name
- NCT00594958
- Testing
- IC51
- Volunteers
- 639 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Rabies, Japanese Encephalitis
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Establish non-inferiority of the immune response and evaluate the safety and tolerability of Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to either of 2 schedules for preexposure…
- Trial name
- NCT01662440
- Testing
- Rabies, Japanese Encephalitis
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 661 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Encephalitis, Japanese
Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose
This study aims to understand the persistence of the Japanese encephalitis (JE) antibody response in previously vaccinated children.
- Trial name
- NCT02514746
- Testing
- Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine
- Volunteers
- 561 people, healthy volunteers welcome
- Sponsor
- PATH
Japanese Encephalitis
Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan
Japanese encephalitis (JE) is one of important zoonotic infectious diseases in Taiwan. JE caused by Japanese encephalitis virus (JEV) which transmitted by Culex tritaeniorhynchus and used swine as amplifying host.
- Trial name
- NCT01163123
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Mennonite Christian Hospital
Japanese Encephalitis
Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj
A multi-center, open, phase 4 clinical trial to assess the long-term immunogenicity and safety of fourth administration of Boryung Cell-Culture Japanese Encephalitis Vaccine inj.
- Trial name
- BR-JELITE (NCT02532569)
- Testing
- Japanese encephalitis vaccine
- Where
- 9 sites in South Korea
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd